



Author Correction: Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population

Correction to: *Nature Communications*
<https://doi.org/10.1038/s41467-024-48780-6>,
published online 28 May 2024

<https://doi.org/10.1038/s41467-024-49655-6>

Published online: 18 June 2024

 Check for updates

William Wang, Nora D. Volkow , Nathan A. Berger , Pamela B. Davis ,
David C. Kaelber  & Rong Xu 

In this article in the abstract the word clinical was misspelt as clinicl. Additionally, on page 2 of the article the sentence ‘Compared to naltrexone or topiramate, semaglutide was associated with a significantly lower risk of incident AUD diagnosis’ was incorrect and should have been ‘Compared to naltrexone or topiramate, semaglutide was associated with a significantly lower risk of recurrent AUD diagnosis’. Finally, on page 8 the sentence ‘Fourth the follow-up time for the main analyses was 8 months’ should have read ‘Fourth the follow-up time for the main analyses was 12 months.’ The original article has been corrected.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2024